Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration

International Journal of Geriatric Psychiatry

Volumn 18, Issue 1, 2003, Pages 67-72

  Pijnenburg, Y A L ^a,c   Sampson, E L ^a   Harvey, R J ^a   Fox, N C ^a   Rossor, M N ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dementia; Extra pyramidal side effects; Frontotemporal lobar degeneration; Neuroleptics; Pick's disease

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; DROPERIDOL; FLUOXETINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; PROCYCLIDINE; PROMAZINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; AGED; AGGRESSION; AKATHISIA; AKINETIC MUTISM; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; BRADYKINESIA; BRAIN DEGENERATION; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; CONSULTATION; CONTROLLED STUDY; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; GAIT DISORDER; HALLUCINATION; HUMAN; HYPOMANIA; LETHARGY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MUSCLE RIGIDITY; PARKINSONISM; PATHOLOGICAL LAUGHTER; PICK PRESENILE DEMENTIA; PSYCHOSIS; RESTLESSNESS; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; SPASMODIC TORTICOLLIS; STATISTICAL SIGNIFICANCE; TEMPORAL LOBE; TREMOR;

EID: 0037239059     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.774     Document Type: Article

References (24)

1. Ayd FJ. 1961. A survey of drug-induced extrapyramidal reactions. J Am Med Assoc 75: 1054-1060.
2. Ballard C, Grace J, McKeith IC, Holmes C. 1998. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 351: 1032-1033.
3. Bazire S. 1999. Psychotropic Drug Directory. Quay Books Division: Dinton.
4. British National Formulary 39th Edition. 2000. British Medical Association and Royal Pharmaceutical Society of Great Britain: London.
5. Foster NL, Wilhelmsen K, Sima AA, et al. 1997. Frontotemporal dementia and Parkinsonism linked to chromosome 17: A consensus conference. Ann Neurol 41: 706-715.
6. Frenchman IB, Prince T. 1997. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioural disturbances. Int Psychogeriatr 9(4): 431-435.
7. Gong CX, Shaikh S, Grundke-Iqbal I, et al. 1996. Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics. Brain Res 741: 95-102.
8. Harvey RJ, Roques P, Rossor MN. 1996. Non-Alzheimer dementias in young patients. Br J Psychiatry 168: 384-385.
9. Lemmens P, Brecher M, Van Buelen B. 1999. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 99: 160-170.
10. Mann DM, South PW, Snowden JS, Neary D. 1993. Dementia of frontal lobe type: Neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiatry 56: 605-614.
11. McGrath AM, Jackson GA. 1996. Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. BMJ 312: 611-612.
12. McKeith I, Fairbairn A, Perry R, et al. 1992. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305: 673-678.
13. Morris HR, Perez TJ, Janssen JC, et al. 1999. Mutation in the tau exon 10 splice site region in familial frontotemporal lobar degeneration. Ann Neurol 45: 270-271.
14. Neary D, Snowden JS. 1996. Clinical features of frontotemporal dementia. In Frontotemporal Dementia, Pasquier F, Lebert F, Scheltens Ph (eds). ICG Publications; 31-47.
15. Neary D, Snowden JS, Gustafson L, et al. 1998. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51: 1546-1554.
16. Pigott MA, Perry EK, McKeith IG, et al. 1994. Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity. Lancet 343: 1044-1045.
17. Pigott MA, Perry EK, Marshall EF, et al. 1998. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: Comparisons with Parkinson's disease. Biol Psychiatry 44: 765-774.
18. Richardson MA, Craig TJ. 1982. The coexistence of Parkinsonism-like symptoms and tardive dyskinesia. Am J Psychiatry 139: 341-343.
19. Schneider LS, Pollock VE, Lyness SA. 1990. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 38: 553-563.
20. Snowden JS, Bathgate D, Varma A, et al. 2001. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 70: 323-332.
21. Tune LE, Steele C, Cooper T. 1991. Neuroleptic drugs in the management of behavioural symptoms of Alzheimer's disease. Psychiatr Clin North Am 14: 353-373.
22. Tyrrell PJ, Warrington E, Frackowiak RSJ, Rossor MN. 1990. Heterogeneity in progressive aphasia due to focal cortical atrophy: A clinical and PET study. Brain 113: 1321-1336.
23. Winiewski HM, Constantinidis J, Wegiel J, et al. 1994. Neurofibrillary pathology in brains of elderly schizophrenics treated with neuroleptics. Alzheimer Dis Assoc Disord 8: 211-227.
24. Woerner MG, Alvir JM, Saltz BL, et al. 1998. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry 155: 1521-1528.